Activation of ERβ hijacks the splicing machinery to trigger R-loop formation in triple-negative breast cancer.
Ontology highlight
ABSTRACT: Triple-negative breast cancer (TNBC) is a subtype of breast cancer with aggressive behavior and poor prognosis. Current therapeutic options available for TNBC patients are primarily chemotherapy. With our evolving understanding of this disease, novel targeted therapies, including poly ADP-ribose polymerase (PARP) inhibitors, antibody-drug conjugates, and immune-checkpoint inhibitors, have been developed for clinical use. Previous reports have demonstrated the essential role of estrogen receptor β (ERβ) in TNBC, but the detailed molecular mechanisms downstream ERβ activation in TNBC are still far from elucidated. In this study, we demonstrated that a specific ERβ agonist, LY500307, potently induces R-loop formation and DNA damage in TNBC cells. Subsequent interactome experiments indicated t
SUBMITTER: Wang D
PROVIDER: S-EPMC10990146 | biostudies-literature | 2024 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA